[language-switcher]
Dr Abdulrahman Ibrahim Al Shaya is Chairman of Collaboration & Partnerships at the King Abdullah International Medical Research Center (KAIMRC), where he leads national and international deal-making across biotechnology investment, cross-border R&D partnerships, and strategic alliances with global institutions, investors, and industry leaders. He also serves as Scientific Advisor to the Saudi Food & Drug Authority and sits on the Ministry of Investment’s National Biotechnology Deal Flow Committee, positioning him at the center of Saudi Arabia’s biotech investment and regulatory landscape. His portfolio includes structuring the Saudi–Japanese Biotechnology Fund and advancing R&D partnerships with global life sciences institutions and investors. He holds an MBA from Texas Tech University and completed postgraduate training through Harvard-affiliated programs at Brigham and Women’s Hospital/Harvard Medical School, bringing a strategy and investment lens to the Kingdom’s Vision 2030 health and biotech ecosystem ambitions.
We’d love to hear from you. Here’s how you can reach us.
General Inquiries
Forbes Middle East is a licensee of Forbes Media and extends the Forbes brand of journalism across the Arab world. Forbes Middle East’s distinctive editorial style attracts a readership of Arab leaders, entrepreneurs, C-level executives, government officials and investors united by a belief in the spirit of free enterprise and entrepreneurial values.Across the region, Forbes Middle East sets the pace for preemptive business journalism. By uncovering trends and anticipating opportunities in the regional marketplace, each monthly issue brings top executives the information critical to their success – in both Arabic and English language editions. The magazine researches and publishes original rankings, based on methodologies set by Forbes Media.